Email not displaying correctly? View it in your browser.
   Volume 4, Issue 1, March 2015
Follow us:   Facebook icon Twitter icon Youtube icon  
Robert B. Diasio, M.D Director's message: Mayo Clinic and multiple myeloma

Researchers continue strong history of advancing myeloma treatment.



New criteria for diagnosing multiple myeloma
Validated biomarkers allow diagnosis before organ damage occurs.


New 3-drug treatment for relapsed multiple myeloma
Drug combo provides unprecedented benefits, including longer remission.


New data show atypical hyperplasia increases breast cancer risk
Findings may spur recommendations for screening MRI, medications.


Nivolumab shows promise for Hodgkin's lymphoma
Early study suggests drug may fight cancer by optimizing immune function.


Genotyping errors plague testing for tamoxifen therapy
Patients, clinicians need more data to assess the value of CYP2D6 testing.


Quality of life may predict survival in aggressive lymphoma
Poor physical, emotional and social well-being may significantly reduce overall survival.


Meet the investigator: Evette S. Radisky, Ph.D.
Dr. Radisky researches proteases in tumor progression and metastasis.

Important Links

Comments Comments?
We're interested in your feedback about this email.
Print Edition Want the Print Edition?
A print edition of Forefront is published annually. To request a free subscription, send your name and mailing address to
Mayo Clinic
Cancer Center

13400 E. Shea Blvd.
Scottsdale, AZ 85259

4500 San Pablo Road
Jacksonville, FL 32224

200 First Street SW
Rochester, MN 55905


Newsletter Archive | Contact Mayo Clinic Cancer Center

© 2015 Mayo Foundation for Medical Education and Research,
200 First Street SW, Rochester, MN 55905.
All rights reserved.
Terms of Use